Mankind Pharma shares slipped over 2% in Friday morning’s trade after the company reported mixed earnings for the September quarter (Q2FY26). As of 9:19 AM, the shares were trading 2.04% lower at Rs 2,261.90.
On a consolidated year-on-year basis, revenue rose 20.8% to ₹3,697 crore compared to ₹3,061 crore in the same quarter last year, driven by healthy growth across its key therapeutic segments. However, profitability came under pressure as EBITDA grew only 8.8% to ₹922 crore from ₹847 crore, while margins contracted to 24.9% from 27.7% a year ago.
Net profit saw a sharper decline of 21.7% to ₹512 crore, down from ₹654 crore in the corresponding quarter of the previous fiscal.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
